TIRAT CARMEL, ISRAEL--(Marketwired - October 18, 2016) - MOTUS GI, a medical device company dedicated to improving colonoscopy outcomes and experiences, announced today the presentation of data demonstrating that the use of the Pure-Vu System during colonoscopy significantly increased the number patients with adequately cleansed colons. The positive data were presented today by Dr. Javier Perez Jimenez, Medical Director of the San Rafael Hospital in Cadiz, Spain, during a session at the United European Gastroenterology Week in Vienna. The presentation is available at www.motusgi.com.
"In as many as 20% of the over 30 million colonoscopies performed worldwide each year, patients are inadequately prepped resulting in increased rates of missed lesions, earlier repeat procedures, prolonged colonoscopy duration, reduced patient satisfaction and increased costs," said Dr. Perez Jimenez. "The Pure-Vu System was found to be simple, safe and effective in cleaning inadequately prepared colons to an adequate level to allow for a thorough exam."
In the study, 50 colonoscopy procedures were conducted at two clinical sites after the patients were given a pre-procedural preparation consisting of only an 18-24 hour liquid diet and bisacodyl tablets to purposely create inadequately prepped colons. No traditional purgative was given. The study endpoints were improvement of colon cleansing levels as per the Boston Bowel Preparation Scoring (BBPS) when comparing before and after Pure-Vu use, Pure-Vu usability via questionnaire, and safety. The Pure-Vu system significantly increased the number of subjects with an adequate cleansing level (BBPS ≥ 2 in each colon segment) from 31% at baseline to 98% after use of the Pure-Vu System (p < 0.001). Physicians reported that they were satisfied with the device's ease of advancement and found it simple and intuitive to operate. The system showed an excellent safety profile with no serious adverse events reported.
"The statistically significant results of this study demonstrate the effectiveness of the Pure-Vu System in cleansing inadequately prepped colons, thereby reducing the sole dependency of pre-procedural prep regimens to achieve a quality exam," said Mark Pomeranz, CEO of MOTUS GI. "Pure-Vu, which obtained FDA clearance last month, provides physicians more flexibility to reliably and consistently achieve visualization of the colon mucosa in their poorly prepped patients. As we prepare for our initial pilot launch in the coming months, our goal is to improve the patient experience and reduce incomplete colonoscopies associated with poorly prepped colons that would require rescheduling or necessitating the need for early repeat procedures."
About Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S. with approximately 50,000 deaths and 140,000 new cases of CRC diagnosed each year. The lifetime risk of developing CRC is about 1 in 20-or 5%. Through the use of colonoscopies, however, CRC has become one of the most preventable cancers.
Colonoscopy is one of the most common medical procedures performed with 15 million procedures performed in the US annually. Approximately 55% percent of colonoscopies are conducted as the standard of care for detecting colorectal cancer (CRC), while the remaining 45% are focused on diagnosis and surveillance of patients with gastrointestinal issues such as bleeding, inflammatory bowel disease and motility challenges.
About MOTUS GI
MOTUS GI is a medical technology company based in Tirat Carmel, Israel. Spun out of the NGT incubator in 2011 by Orchestra Medical Ventures, the company is focused on the development and commercialization of the Pure-Vu System to improve the colonoscopy experience for physicians, patients and payers by enhancing the quality and cost-effectiveness of the exam. The Pure-Vu System is indicated to connect to standard colonoscopes to perform intra-procedural cleaning of a poorly prepared colon, thereby reducing the sole dependency on a successful pre-procedural prep regimen to gain clear visualization of the colon mucosa. For more information, visit www.motusgi.com.
This press release contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.